SEC Tracker
Get the app

Mycotopia Therapies AIBT

Mycotopia Therapies FY 2022: net loss $2.6M

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Mycotopia Therapies reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$2.6MAgainst −$5.1M in FY 202110-K/A income statement, on EDGAR
  2. Cash and cash equivalents$386K−70% from $1.3M in FY 202110-K/A balance sheet, on EDGAR
  3. Cash from operations−$657KAgainst −$235K in FY 202110-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Mycotopia Therapies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2833) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Twinlab Consolidated Holdings TLCC public float $1M, Jun 30, 2025
  2. China Foods Holdings CFOO public float $864K, Jun 30, 2025
  3. Nutra Pharma NPHC public float $703K, Jun 30, 2025
  4. Cannaisseur Group TCRG public float $3M, Jun 30, 2025
  5. Functional Brands MEHA public float $4M, Dec 31, 2025